Muammar Kabir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Muammar Kabir has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Larisa G. Tereshchenko
Quantitative Health Sciences, Cleveland Clinic Research, Cleveland, Ohio, USA
3 shared publications - Azadeh Yadollahi
University of Toronto
2 shared publications Bojan Gavrilovic
KITE-Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada
2 shared publications- Erick Andres Perez Alday
Knight Cardiovascular Institute, Oregon Health and Science University, Portland, USA
2 shared publications Golriz Sedaghat
Knight Cardiovascular Institute, Oregon Health and Science University, Portland, USA
2 shared publications- Jason Thomas
Knight Cardiovascular Institute, Oregon Health and Science University, Portland, USA
2 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500073
Development of Machine Learning Systems to Predict Cancer-Related Symptoms With Validation Across a Health Care System
PURPOSE: Cancer and its treatment cause symptoms. In this study, we aimed to develop machine learning (ML) systems that predict future symptom deterioration among people receiving treatment for cancer and then validate the systems in a simulated deployment across an entire health care system. METHODS: We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) data at Princess Margaret Cancer Centre (3,229 patients; 20,267 treatments). The primary performance metric was the area under the receiver operating characteristic curve (AUROC). The best-performing systems in the held-out internal test set were then externally validated across 82 cancer centers in Ontario (12,079 patients; 77,003 treatments) by adapting techniques from meta-analysis. RESULTS: The best ML systems predicted symptom deterioration with AUROCs ranging from 0.66 (95% CI, 0.63 to 0.69) for dyspnea to 0.73 (95% CI, 0.71 to 0.75) for drowsiness in the internal test cohort. Treatments flagged as high-risk were significantly associated with future symptom deterioration (odds ratios [ORs], 2.53-6.56; all P < .001) and emergency department visits for dyspnea (OR, 1.85; P = .008), depression (OR, 1.84; P = .04), and anxiety (OR, 2.66; P < .001). In the external validation cohort, the AUROCs for different symptoms meta-analyzed across centers ranged from 0.67 (95% CI, 0.66 to 0.68) to 0.73 (95% CI, 0.72 to 0.74). Performance across centers displayed significant heterogeneity for six of nine symptoms (I 2 , 46.4%-66.9%; P = .004 for dyspnea, P < .001 for the rest). CONCLUSION: ML can predict future symptoms among people with cancer from routine EHR data, which could guide personalized interventions. Heterogeneous performance across centers must be considered when systems are deployed across a health care system.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500073
Open AccessDevelopment of Machine Learning Systems to Predict Cancer-Related Symptoms With Validation Across a Health Care System
PURPOSE: Cancer and its treatment cause symptoms. In this study, we aimed to develop machine learning (ML) systems that predict future symptom deterioration among people receiving treatment for cancer and then validate the systems in a simulated deployment across an entire health care system. METHODS: We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) data at Princess Margaret Cancer Centre (3,229 patients; 20,267 treatments). The primary performance metric was the area under the receiver operating characteristic curve (AUROC). The best-performing systems in the held-out internal test set were then externally validated across 82 cancer centers in Ontario (12,079 patients; 77,003 treatments) by adapting techniques from meta-analysis. RESULTS: The best ML systems predicted symptom deterioration with AUROCs ranging from 0.66 (95% CI, 0.63 to 0.69) for dyspnea to 0.73 (95% CI, 0.71 to 0.75) for drowsiness in the internal test cohort. Treatments flagged as high-risk were significantly associated with future symptom deterioration (odds ratios [ORs], 2.53-6.56; all P < .001) and emergency department visits for dyspnea (OR, 1.85; P = .008), depression (OR, 1.84; P = .04), and anxiety (OR, 2.66; P < .001). In the external validation cohort, the AUROCs for different symptoms meta-analyzed across centers ranged from 0.67 (95% CI, 0.66 to 0.68) to 0.73 (95% CI, 0.72 to 0.74). Performance across centers displayed significant heterogeneity for six of nine symptoms (I 2 , 46.4%-66.9%; P = .004 for dyspnea, P < .001 for the rest). CONCLUSION: ML can predict future symptoms among people with cancer from routine EHR data, which could guide personalized interventions. Heterogeneous performance across centers must be considered when systems are deployed across a health care system.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 16, 1623-1636
Unveiling the Impact of Respiratory Event-Related Hypoxia on Heart Sound Intensity During Sleep Using Novel Wearable Technology
Purpose: Cardiovascular disorders are the leading cause of mortality worldwide with obstructive sleep apnea (OSA) as the independent risk factor. Heart sounds are strong modalities to obtain clinically relevant information regarding the functioning of the heart valves and blood flow. The objective of this study was to use a small wearable device to record and investigate the changes in heart sounds during respiratory events (reduction and cessation of breathings) and their association with oxyhemoglobin desaturation (hypoxemia). Patients and Methods: Sleep assessment and tracheal respiratory and heart sounds were recorded simultaneously from 58 individuals who were suspected of having OSA. Sleep assessment was performed using in-laboratory polysomnography. Tracheal respiratory and heart sounds were recorded over the suprasternal notch using a small device with embedded microphone and accelerometer called the Patch. Heart sounds were extracted from bandpass filtered tracheal sounds using smoothed Hilbert envelope on decomposed signal. For each individual, data from 20 obstructive events during Non-Rapid Eye Movement stage-2 of sleep were randomly selected for analysis. Results: A significant increase in heart sounds’ intensities from before to after the termination of respiratory events was observed. Also, there was a significant positive correlation between the magnitude of hypoxemia and the increase in heart sounds’ intensities (r> 0.82, p< 0.001). In addition, the changes in heart sounds were significantly correlated with heart rate and blood pressure. Conclusion: Our results indicate that heart sound analysis can be used as an alternative modality for assessing the cardiovascular burden of sleep apnea, which may indicate the risk of cardiovascular disorders.
- 1 October 2024
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 16, 1623-1636
Open AccessUnveiling the Impact of Respiratory Event-Related Hypoxia on Heart Sound Intensity During Sleep Using Novel Wearable Technology
Purpose: Cardiovascular disorders are the leading cause of mortality worldwide with obstructive sleep apnea (OSA) as the independent risk factor. Heart sounds are strong modalities to obtain clinically relevant information regarding the functioning of the heart valves and blood flow. The objective of this study was to use a small wearable device to record and investigate the changes in heart sounds during respiratory events (reduction and cessation of breathings) and their association with oxyhemoglobin desaturation (hypoxemia). Patients and Methods: Sleep assessment and tracheal respiratory and heart sounds were recorded simultaneously from 58 individuals who were suspected of having OSA. Sleep assessment was performed using in-laboratory polysomnography. Tracheal respiratory and heart sounds were recorded over the suprasternal notch using a small device with embedded microphone and accelerometer called the Patch. Heart sounds were extracted from bandpass filtered tracheal sounds using smoothed Hilbert envelope on decomposed signal. For each individual, data from 20 obstructive events during Non-Rapid Eye Movement stage-2 of sleep were randomly selected for analysis. Results: A significant increase in heart sounds’ intensities from before to after the termination of respiratory events was observed. Also, there was a significant positive correlation between the magnitude of hypoxemia and the increase in heart sounds’ intensities (r> 0.82, p< 0.001). In addition, the changes in heart sounds were significantly correlated with heart rate and blood pressure. Conclusion: Our results indicate that heart sound analysis can be used as an alternative modality for assessing the cardiovascular burden of sleep apnea, which may indicate the risk of cardiovascular disorders.
- 1 May 2020
- Published by Elsevier in Sleep Medicine
- Vol. 69, 51-57
Portable diagnosis of sleep apnea with the validation of individual event detection
- 1 May 2020
- Published by Elsevier in Sleep Medicine
- Vol. 69, 51-57
Portable diagnosis of sleep apnea with the validation of individual event detection
- 1 November 2018
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 102, 242-250
The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator
- 1 November 2018
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 102, 242-250
The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator
- 1 January 2018
- Published by Elsevier in Journal of Electrocardiology
- Vol. 51 (1) , 60-67
Torso geometry reconstruction and body surface electrode localization using three-dimensional photography
- 1 January 2018
- Published by Elsevier in Journal of Electrocardiology
- Vol. 51 (1) , 60-67
Torso geometry reconstruction and body surface electrode localization using three-dimensional photography
- 1 November 2016
- Published by Elsevier in Journal of Electrocardiology
- Vol. 49 (6) , 931
Quantitative Assessment of Vectorcardiographic Loop Morphology
- 1 November 2016
- Published by Elsevier in Journal of Electrocardiology
- Vol. 49 (6) , 931
Quantitative Assessment of Vectorcardiographic Loop Morphology